



INDEX

A

- Abciximab, 168
- Abdominal assessment, 81
- Absorption, age-related changes in, 68
- Abuse, elderly, 41
- Acamprosate, 401
- Acarbose, 261, 267
 - diarrhea and, 312
- Access-A-Ride, 96
- ACCORD trial, 270–271
- ACCORD BP trial, 162–163
- Accu-Check Compact®, 270
- ACE inhibitors. *See* Angiotensin-converting enzyme inhibitors
- Acetaminophen, 110, 301, 425–426, 430, 444–447
 - heart failure and, 177
 - in hospice and palliative care, 134
 - terminally ill and, 133
- Acetazolamide, 420
- Acetylcholinesterase inhibitor(s), 230, 237–238, 312, 356
- Acrylic dressings, 464
- Activities of daily living (ADLs), 8, 10–11, 77, 92, 341
- Actos, 261
- Acute care, 10
- Acute Care for Elders (ACE) units, 12
- Acute coronary syndromes, 167–170
- Acute pain, 424
- ADAGIO trial, 351
- Adaptive immunity, 515, 516, 517
- ADEs. *See* Adverse drug events
- Adenosylmethionine (SAME), 445
- ADLs. *See* Activities of daily living
- Administration on Aging, 10
- ADRs. *See* Adverse drug reactions
- Adrenergics, 419
- Adrenocorticotrophic hormone, 278
- Adult day centers, 11
- Adult Protective Services, 41
- Advance directives, 37–39, 77, 94–95
- ADVANCE trial, 271
- Adverse drug events (ADEs), 105–106, 110–112, 116–117
 - medication sensitivity and, 68–69
 - opportunities to improve drug use and, 113–115
 - reduction in, 112–113
 - therapeutic failure and, 112
 - transitions in care and, 118
 - Adverse drug reaction (ADR), 105–106, 110–111
- Adverse drug withdrawal events (ADWEs), 105–106, 111–112
- Advisory Committee on Immunization Practices (ACIP), 488, 490–491
- ADWEs. *See* Adverse drug withdrawal events
- Affordable Care Act (ACA), 46–47
- African American culture, 35, 39
- Age, 4–5
- Age strata, 5
- Agency for Healthcare Research and Quality, 344
- Age-related changes, 74
- Age-Related Eye Disease Research Group, 421
- Age-Related Eye Disease Study, 422–423
- Age-related macular degeneration, 421
- Aging theories, 58–59
- Agitation, 13, 142–143, 342–343
- Albuterol, 142, 202, 211, 218, 540
- Alcohol abuse/alcoholism/use, 94, 396–398, 447, 485–486, 530
 - binge drinking, 177

- delirium and, 345
- dysphagia and, 299
- insomnia and, 381
- withdrawal, anxiety and, 381
- Alcohol Use Disorders Identification Test (AUDIT), 398
- Aldosterone antagonists, 173, 174, 176
- Alendronate, 449, 451, 453, 454, 455
- ALF. *See* Assisted living facility
- Alfuzosin, 234, 244, 245
- Alginate, 462, 464
- Alli, 262
- Alogliptin, 268
- Alpha agonists, hypertension and, 163
- Alpha-1 adrenergic blockers, 164, 174
- Alpha-adrenergic agonists, 233, 243, 419–420
- Alpha-adrenergic blockers/antagonists, 243–245
 - pharmacodynamic changes, recommendations for, 71
- Alpha-antagonists, hypertension and, 163
- Alpha-glucosidase inhibitors, 263–264, 267
- Alpha-receptor agonist, 160
- Alpha-receptor antagonist, 159
- Alprazolam, 402
- Alteplase, 168
- Altered taste, 293, 295
- Altered vision, 6
- Alternative medicine, 36
- Alvimopan, 309
- Alzheimer disease, 461, 487
 - central nervous system issues and, 337–341, 344, 360
 - TSH concentrations and, 275
- Alzheimer's Disease Assessment Scale–cognitive subscale (ADAS-cog), 89
- Alzheimer's Disease Cooperative Study ADL (ADCS-ADL) Inventory, 92
- Amantadine, 350, 490, 532
- Amaryl, 261
- American Academy of Family Physicians, 340
- American Academy of Neurology, 349, 351–352, 356
- American Academy of Pain Medicine, 425
- American Association of Clinical Endocrinologists, 449
- American Association of Retired Persons (AARP), 4
- American Board of Internal Medicine Foundation, 497
- American Cancer Society, 81, 494–497, 500
- American College of Cardiology, 161–163, 171–172, 177, 225
- American College of Chest Physicians, 171, 177, 185–187
- American College of Gastroenterology, 303
- American College of Physicians, 340
- American College of Rheumatology, 444, 456–457
- American Dental Association, 295
- American Diabetes Association, 259, 260, 268
- American Epilepsy Society, 356
- American Geriatrics Society, 9, 107, 268, 426, 441, 443, 497, 525
 - Panel on Improving Care for Elders with Diabetes, 260
 - Panel on the Pharmacological Management of Persistent Pain, 133
- American Heart Association, 161–163, 171–172, 177, 183, 225, 295–296
 - physical activity guidelines, 93
- American Medical Association, 39
- American Pain Society, 425
- American Red Cross, 18
- American Society of Consultant Pharmacists, 8
- American Society for Nutrition, 272
- American Stroke Association, 172, 183
- American Thoracic Society, 212, 529, 531
- American Urological Association, 232, 243
 - Benign prostatic hyperplasia symptom score, 240
 - Symptom Index (AUA-SI), 239, 241–242, 243
- Aminoglycosides, 419
 - distribution and, 68
 - hearing loss and, 63
- Amiodarone, 228
 - altered taste and, 295
 - atrial fibrillation and, 178
 - dementia and, 335
 - hypothyroidism and, 275–276
- Amitriptyline
 - central nervous system issues and, 351
 - as high-risk medication, 107
 - pain/sensory issues and, 426–427, 429, 434
- Amobarbital, high-risk medication, 107
- Amoxicillin, 295
- Amoxicillin/clavulanate, 523
- Amoxicillin/clavulanate plus macrolide, 523
- Amphetamine, toxicity, 295
- Ampicillin, 523
- Ampicillin/sulbactam plus macrolide, 523
- Amylin analog, 264, 267
- Analgesics, 228, 345
- Anastrozole, 455
- Androgel, 282
- Androgens, 282–283
- Andropause, 279–280
- Anemia, 480–488
 - case, 502–503
 - of chronic disease, 484
 - of chronic inflammation/kidney disease, 482
 - of chronic kidney disease, 484, 486–487
 - of inflammation, 484, 486–487
- Angiotensin-converting enzyme (ACE) inhibitor(s), 110, 225, 228
 - adverse drug withdrawal event and, 111
 - arginine vasopressin (ADH) and, 227–228
 - chronic kidney disease and, 225
 - coronary events and, 168–169

- diarrhea and, 312
- heart failure and, 173–176
- hypertension and, 161–163
- pharmacodynamic changes, recommendations for, 71
- pharmacotherapy of, 162–164, 168–170, 173–176
- stress incontinence and, 230
- Angiotensin II receptor blockers, 164
- Angiotensin receptor blockers (ARBs), 225
 - hypertension and, 161, 163
- Anorexia, 139, 141
- Antacids, 447, 301
- Anti-aging strategies, 65–66
- Anti-allergen, 206
- Antibiogram, 515, 518
- Antibiotic stewardship, 519, 521
- Antibiotics, 463, 517–518, 520, 530. *See also specific antibiotics*
- Anticholinergics, 305, 310, 419, 528
 - anxiety and, 381
 - chronic obstructive pulmonary disease and, 207–208
 - delirium and, 345
 - drug-disease interactions of, 107–108
 - dysphagia and, 297
 - functional decline and, 66
 - inhaled bronchodilators and, 200, 202, 211
 - insomnia and, 381
 - nausea/vomiting and, 140, 305
 - overflow incontinence and, 231
 - pharmacodynamic changes, recommendations for, 71
 - terminal secretions and, 143
 - urinary retention and, 230
- Anticoagulants, 110, 296, 447
 - adverse drug reactions and, 111
 - diabetes and, 269
- Anticonvulsants, 214, 228, 427, 455
 - delirium and, 345
 - dementia and, 335
 - depression and, 381
 - diarrhea and, 312
 - dosing of, 71
 - drug-disease interactions of, 107, 108
 - dying patient and, 133
 - endocrine disorders and, 271, 282
 - falls and, 441
 - tapering of, 114
- Antidepressants, 184, 425
 - adverse drug withdrawal events and, 111–112
 - anxiety and, 381
 - falls and, 441
 - insomnia and, 381
 - psychiatric disorders and, 381–382, 402
 - renal/urologic disorders and, 228, 243
 - tapering of, 114
 - withdrawal and, 131
- Antidiabetics
 - delirium and, 345
 - See also specific antidiabetics*
- Anti-diuretic hormone (ADH), 221, 227–228
- Antiepileptics, 184, 425–426
 - drug-disease interactions, 365–366
- Antihistamines, 140, 243, 394, 305
- Antihypertensives, 466
- Antimicrobials
 - delirium and, 345
 - dressings, 465
- Antimicrobial stewardship, 515, 519
- Antineoplastics, 228
 - diarrhea and, 312
- Antioxidants
 - supplements, 421
 - therapy, anti-aging and, 65
- Antiparkinson medications, 111–113, 228
- Antiplatelet agents/therapy, 110, 296, 447
 - GERD and, 304
 - underuse of, 109
- Antipsychotics, 344, 419, 466
 - adverse drug withdrawal events and, 111
 - agitation and, 143
 - delirium and, 348
 - distribution and, 69
 - drug-disease interactions by, 108
 - dysphagia and, 297
 - falls and, 441
 - functional decline and, 66
 - GERD and, 303
 - hyperglycemia and, 288
 - pharmacodynamic changes, recommendations, 71
 - renal/urologic disorders and, 228, 243
- Antispasmodics, 308
- Antithrombotic therapy, 110, 157, 171
- Antithrombotic Trialists' Collaboration, 171, 184
- Anti-tumor necrosis factor (TNF)-alpha, 213, 457–458
- Anti-vascular endothelial growth factor, 421
- Anxiety, 137–138, 385–392
 - diagnostic criteria for, 387–388
- Apixaban, 179–180, 182
- Apomorphine, 350, 351, 354
- Apoptosis, 59
- Appetite stimulants, 184
- Apraclonidine, 420
- Aprepitant, 306
- Aranesp, 487
- ARBs. *See* Angiotensin receptor blockers
- Area Agencies on Aging, 19
- Arginine vasopressin (AVP), 221, 227–228
- Aricept, 340
- Aripiprazole, 348

ARISTOTLE trial, 180
 Armour thyroid, 262
 Aromatase inhibitors, 282
 Artificial nutrition, 39
 Asal, Nicole J., 221–256
 Ascorbic acid, 485
 Aspiration pneumonia, 293, 294, 298–299, 529–530
 Aspirin, 110, 448, 499

- antithrombotic therapy and, 170, 181
- bleeding and, 181
- frail elderly patient and, 54
- GERD and, 303
- low dose, 260, 460
- peripheral arterial disease and, 171–172
- secondary prevention of coronary events with, 168, 169
- STEMI, NSTEMI and, 168
- stopping, 131
- stroke prevention, 178–179, 183–185

 Aspirin–extended-release dipyridamole, 183, 185
 Assessing Care of Vulnerable Elders (ACOVE), 109, 110
 Assessment of Underutilization (AOU), 109
 Assisted living facility (ALF), 3, 8, 10–11, 17
 Assisted suicide, 40
 Asthma, 200–201, 208–211

- case, 215–216
- commonly used drugs in, 202–206
- inhaler technique for, 201

 Asymptomatic bacteriuria, 515, 522, 524, 526
 Atorvastatin, 167, 179
 Atrial fibrillation, 177–182
 Atropine, 137
 Atypical disease presentation, 78–79, 100

- respiratory disorders and, 218
- infections and, 515, 518, 521, 526–527, 529, 540

 AUDIT, 398
 Auscultatory gap, 79, 162, 173, 193
 Authorization, 34
 Autonomy, 29, 30, 54
 Avanafil, 263, 281
 Avandia, 261
 Azathioprine, 312, 486
 Azithromycin, 295, 530

B

B cells, 517
 Baby Boomer generation, 36
 Bacillus Calmette-Guérin (BCG) vaccine, 212
 Bacteriuria, 527–528. *See also* Asymptomatic bacteriuria
 Balance, 93
 Barbiturates, 46

- drug-disease interactions by, 365
- dysphagia and, 297

 Bariatric surgery, 273
 Beclomethasone dipropionate, 203
 Bedrails, 442
 Bedside assessment, 82–83
 Beers criteria, 107

- central nervous system and, 342, 353–354
- pain/sensory disorders and, 428
- pharmacotherapy and, 175–176, 178, 180

 Behave-AD (Behavioral Pathology in Alzheimer's Disease Rating Scale), 91
 Behavioral therapy, 273
 Belgeri, Myra T, 377–416
 Belviq, 262
 Beneficence, 29, 30, 32
 Benign prostatic hyperplasia (BHP), 237–239, 522

- dietary supplements and, 246–247
- surgery for, 247

 Benzodiazepine-receptor agonists, 394–395, 407
 Benzodiazepines, 46, 214, 344, 425

- adverse drug reactions with, 111
- adverse drug withdrawal events with, 112, 381
- anxiety and, 138, 381
- delirium and, 143, 348
- dementia and, 335, 339
- depression and, 381
- distribution and, 69
- drug-disease interactions by, 108, 365
- dyspnea and, 142
- falls and, 441
- functional decline and, 66
- insomnia and, 381
- nausea/vomiting and, 140
- pharmacodynamic changes, recommendations for, 71
- psychiatric treatment with, 390–392, 394, 399–400, 402, 407
- respiratory drive and, 210
- secretion reduction and, 130
- seizures and, 356

 Benzotropine, 350, 354

- as high-risk medication, 107

 Berg Balance Scale (BBS), 93
 Beta adrenergic blockers, 164
 Beta agonists, 200, 201, 208, 211

- insomnia and, 381

 Beta amyloid, 334, 337
 Beta blockers, 110, 160, 168, 301, 448

- angina and, 133
- coronary events and, 169
- depression and, 381
- dry mouth and, 295
- diarrhea and, 312
- heart failure and, 173–176
- hypertension and, 163
- STEM1 and, 169–170

ventricular rate control and, 178
 withdrawal and, 131

Beta carotene, 500–501

Beta-adrenergic blockers, 71, 276–277, 421

Beta-lactam/beta-lactamase, 530

Betaxolol, 420

Bevacizumab, 421, 423–424

Bifidobacterium, 310

Biguanides, 263

Bile acid sequestrant, 265

Bimatoprost, 420–422

Binswanger disease, 338

Biologic dressings, 465

Biologic response modifiers (BRMS), 439, 457–458

Biological clock, 59

Biological products, 45

Biomarkers, 516–517

Biomedical aging model, 64

Biomedical ethics, 30–32, 37, 54

Biomedical principles, 57–58
 emergency department case, 72–73
 medication sensitivity and aging, 68–71
 pharmacodynamic changes, recommendations and, 71
 pharmacotherapy adage for, 74
 physiology of growing older, 58–68

Birth defects, 252

Bisacodyl, 133

Bisoprolol, 173, 176

Bisphosphonates, 110, 133, 449, 451, 454, 459
 atrial fibrillation and, 177
 cognitive function and, 6
 diarrhea and, 312
 dysphagia and, 297
 GERD and, 303
 osteoporosis and, 209

Bivalirudin, 168

Bladder
 anatomy, physiology, 229
 training, 232

Bladder antispasmodics
 dry mouth and, 294
 health or functional status and, 6

Bladder outlet obstruction (BOO), 231, 239, 243–244, 245

Blaszczyk, Amie Taggart, 333–376

Blood glucose monitoring, 269–270, 288

Blue Mountains Eye Disease Study, 422

Bone loss, 62–63

Boost, 319

Boxed warning, 29, 30

Braden scale, 461

Breakthrough pain, 417, 425

Breast cancer
 chemoprevention, 498–499
 screening, 494–495

Breast Cancer Prevention Trial, 408

Breathlessness quantification, 201

Brimonidine, 420, 423

Brimonidine and brinzolamide, 422

Brimonidine and timolol, 422

British Doctors Aspirin Trial, 499

British Thoracic Society, 531

Brodeur, Michael R., 199–220

Bromocriptine, 264, 268, 350, 351

Brompheniramine, high-risk medication, 107

Bronchodilators, 202, 204
 altered taste and, 295
 dyspnea and, 142

“Brown bag” medication, 14–15

Budesonide and formoterol, 204

Bulking agents, 309–311

Bupropion, 283, 364, 381–382, 384

Buspiron, 386, 391
 anxiety and, 138
 in hospice and palliative care, 137
 toxicity of, 295

Butabarbital, high-risk medication, 107

Butalbital, high-risk medication, 107

Butyrophenones, 140

Byetta, 261

C

C. pneumoniae, 529

Cachexia, 316, 319

Caffeine, 381

CAGE questionnaire, 398

Calcitonin, 312

Calcitonin, nasal, 449, 452

Calcium, 277, 450, 455
 dietary, 453
 supplemental, 500–501

Calcium alginates, 464

Calcium carbonate, 113, 453

Calcium channel blockers, 164, 310
 angina and, 133
 dry mouth and, 295
 GERD and, 303
 heart failure and, 173
 hypertension and, 161, 163
 pharmacodynamic changes, recommendations for, 71
 urinary retention and, 230

Calcium citrate, 453

Calcium oxalate stones, 525

Calcium/vitamin D therapy, 448

Calorie restriction therapy, anti-aging and, 65

Canadian Hypertension Education Program, 162

Canagliflozin, 262, 268

Cancer
 chemoprevention, 479, 498–501

- prevention, 494
- Cancer screening, 492–501
 - case, 504–505
- Cancer-related checkup, 497
- Cannabinoids, 141, 305
- CAPRIE trial, 171
- Caprylidene, 341
- Capsaicin topical, 426–427, 444–445
- Captopril, functional decline and, 66–67
- Carbachol, 420
- Carbamazepine, 370, 427
 - adverse drug withdrawal events and, 112
 - diarrhea and, 312
 - drug-disease interactions by, 365, 366
 - hypothyroidism and, 277
 - seizures and, 356, 357, 360, 362
- Carbidopa, 350
- Carbinoxamine, high-risk medication, 107
- Carbonic anhydrase inhibitors, 419, 420
- Cardiovascular assessment, 80–81
- Cardiovascular changes, 59
- Cardiovascular disease
 - acute coronary syndromes, 167–170
 - antihypertensives, 164
 - atrial fibrillation, 177–182
 - coronary artery disease, 167–170
 - diabetes mellitus, 260
 - dyslipidemia, 165–167
 - heart failure, 172–177, 193
 - hypertension, 160–163, 193
 - lipid management, 165–167
 - orthostatic hypotension, 158–160, 191–192
 - peripheral artery disease, 170–172
 - stroke, 182–185
 - venous thromboembolism, 185–188, 189–190
- Cardiovascular Health Study, 173
- Cardiovascular risk factors, 225–226
- Cardiovascular system, age-related changes in, 70–71
- Care venues
 - Interprofessional teams, 8
 - moving from one to another, 13–14
 - nurses, 7–8
 - other health professionals, 8
 - pharmacists, 8
 - physicians, 7
- Care-based thinking, 32
- Caregiver, 17–18
 - characteristics of, 18
- Caregiver Burden Inventory, 19
- Caregiver burden, 3, 18, 128
 - measuring, 19
 - resources and strategies, 19–20
- Caregiver Activity Survey, 19
- Caregiver Strain Index, 19
- Caregiver's Burden Scale in End-of-Life Care, 19
- Care-recipient characteristics, 18
- Carisoprodol, high-risk medication, 108
- Carotenoids, 422
- Carvedilol, 173, 174, 176
- CAST trial, 184
- Cataracts, 419, 421–422
- Catastrophic Coverage, 45
- Cefepime, 523
- Cefotaxime plus macrolide, 523
- Ceftazidime, 523
- Ceftriaxone, 523
- Center for Evidence-Based Dentistry, 295
- Centers for Disease Control and Prevention (CDC), 212, 313, 443, 533–534
- Centers for Medicare & Medicaid Services (CMS), 12, 44, 46, 114, 344, 463
- Central nervous system (CNS), age-related changes in, 59–60, 71
- Cephalexin, 525
- Cephalosporins, 295, 312–313, 364, 523
- Certified geriatric pharmacist, 3, 8, 9
- Certified nurse's assistant, 3, 7, 9
- Cervical cancer screening, 496
- CHADS score, 178–180
- Charcoal dressing, 465
- Charlson Comorbidity Index, 111
- Chemical restraint, 334, 347
- Chemotherapeutic agents, 304
- Chemotherapy agents, altered taste and, 295
- Cheng-Lai, Angela, 479–513
- Chest x-ray, 496–497, 529, 540
- Child-Pugh, 245
 - class B, 458
- Chloral hydrate, high-risk medication, 107
- Chlorhexidine, 296
- Chlorpheniramine, high-risk medication, 107
- Chlorpromazine
 - delirium and, 143
 - in hospice and palliative care, 136
- Chlorpropamide, 261, 266
 - high-risk medication, 108
- Chlorzoxazone, high-risk medication, 108
- Choices, respecting, 32–33
- Choking risk, 298
- Cholestyramine, 486
- Cholinergics, 111
- Cholinesterase inhibitors (CI), 184, 528
 - central nervous system disorders and, 337, 339–342, 344, 355, 364, 370
- Cholinesterase inhibitors, GERD and, 303
- Chondroitin, 445
- Choosing Wisely campaign, 497–498
- Christianity, 37
- Chronic care, 10
- Chronic kidney disease (CKD), 222–228
- Chronic Kidney Disease Epidemiology Collaboration GFR formula, 70

- Chronic obstructive pulmonary disease (COPD),
200–201, 208–211, 218
Assessment Test, 201
case, 217
commonly used drugs in, 202–206
inhaler technique for, 201
therapy at each state of, 207
- Cialis, 263
- Ciclesonide, 203
- Cilostazol, 171, 172
- Cimetidine
depression and, 381
elimination of, 70
- Ciprofloxacin, 307
- Citalopram, 389
depression, 138
FDA warning for, 383
in hospice and palliative care, 136
- Clarithromycin, 295
- Clemastine, high-risk medication, 107
- Clindamycin, 295, 312–313, 523
- Clindamycin plus fluoroquinolone, 530
- Clinical global impression of improvement (CGI-I),
377, 390
- Clinical Institute Withdrawal Assessment (CIWA),
398–400
- Clinical literature
Applicability of, 6–7
subgroup perspective case for, 21–22
- Clinical Swallow Evaluation, 298
- Clinical Trial of Nutritional Supplements, 422
- Clinician's Interview Based Impression of Change-
Plus Caregiver Input (CIBIC-Plus), 88, 91, 341
- Clomipramine, high-risk medication, 107
- Clonazepam, 366, 402
- Clonidine, 228
depression and, 381
dry mouth and, 294–295
- Clonidine topical, 129
- Clopidogrel
antithrombotic therapy and, 171
fibrinolytics and, 169
kidney disease and, 185
NSTEM1 and, 168
peripheral arterial disease and, 171–172
stroke prevention and, 179, 183
- Clostridium difficile* diarrhea, 303–304, 313–315,
518–519, 527
case, 321–322
- Clostridium tetani*, 491
- Clozapine, 338, 355
- Coagulase-negative *Staphylococcus*, 518
- Cochrane database review, 172
- Cockcroft-Gault equation, 70, 82, 223
- Codeine, 112, 312
- Coenzyme Q10, 351
- Cognition diseases, 336
- Cognitive assessment, 84–89
- Cognitive behavioral therapy, 377, 382, 386, 389,
391, 394
- Cognitive function, 5–6
- Cognitive impairment
anemia and, 487
blood glucose assessment with, 288
hypoglycemia and, 271–272
inhaler use with, 210
pain assessment with, 128, 428
- Cohen, Lisa B., 257–292
- Colchicine, 112, 312
- Colesevelam, 268
- Colestipol, 277
- Collagen injection, 311
- Colon cancer chemoprevention, 499–500
- Colonoscopy, 495
- Colorectal cancer screening, 495–496
- ComBAT study, 246
- Comfort care, 123, 125
- Commission for Certification in Geriatric Pharmacy,
8, 9
- Communication, 33, 54
- Community pharmacist, 10, 15
- Community pharmacy, ethics case, 52–53
- Comorbidities, 111
- Competence, patient, 33
- Composite dressings, 464
- Confidentiality, 34
- Confusion, 259–260
- Confusion Assessment Method, 345–346, 519
- Conjugated estrogen, 108, 234
- Connective tissue changes, 62
- Constipation, 64, 133, 308–311, 428
- Consultant pharmacist, 12, 15–16, 17
- Continuous care retirement communities, 11
- Cook, Kristen M., 157–198
- Coordination, 6
- Coordination of care, 23–24
- COPD, *See* Chronic obstructive pulmonary disease
- Cornell Scale for Depression in Dementia, 91
- Coronary artery disease, 167–170, 281–282
- Corticosteroid eye drops, 420
- Corticosteroids, 419, 528, 530
anorexia and, 139
- COPD/asthma and, 201, 203–207, 209, 212, 214
delirium and, 345
dementia and, 335
insomnia and, 381
nausea/vomiting and, 140
tapering of, 114
terminally ill and, 133
- Count-A-Dose, 267
- Coverage gap, 45
- COX-2 inhibitors, 296, 446–447

Cranberry, 524
 Creatinine clearance, 70
 Creutzfeldt-Jakob disease, 339
 Cromolyn, 201
 Cromolyn sodium, 205
 Crushed medications, 300–302, 355
 Culture, 29, 33, 34–35, 37, 64, 125
 CURB-65, 531
 CURE trial, 172
 Cushing syndrome, 461
 Cyclobenzaprine, high-risk medication, 108
 Cyclosporine, topical, 420, 422
 Cyproheptadine, high-risk medication, 107
 Cystitis, 522
 Cytomel, 262
 Cytotoxic medications, 295

D

Dabigatran, 31, 178–182
 Dalteparin, 187
 Damage theories of aging, 58
 Dapagliflozin, 262
 Darbepoetin-alfa, 487
 Darifenacin, 234, 235, 236
 DATATOP trial, 351
 Dayer, Lindsey, 123–154
 Death, 124–125, 149
 rattle, 123, 143
 signs preceding, 132
 Debridement, 439, 462
 Decision making, 54
 shared, 37
 surrogate, 37–38, 39
 Decongestants, insomnia and, 381
 Deep vein thrombosis case, 189–190
 Dehydration, 226–227
 Delirium, 64, 142–143, 344–348, 370
 case, 367
 Delirium tremens, 94
 Dementia, 111, 335–344, 370
 depression in, 91
 heart failure and, 177
 hyperosmolar hyperglycemic nonketotic syndrome and, 272
 informed consent and, 34
 screening for, 86–87
 stroke and, 183
 TSH concentration and, 276
 urinary incontinence and, 238, 248–249
 Dementia with Lewy bodies, 338, 344
 Dementia Mood Assessment Scale, 91
 Denosumab, 449, 452, 454, 455
 bone pain and, 133
 in hospice and palliative care, 136
 Dental care, 271
 Dental procedures, 295–296
 Denture cleaning, 296–297
 Denture stomatitis, 294
 Depressants, 345
 Depression, 137–138, 379–385
 assessment of, 89–91
 case, 403–404
 Dermatome, 417, 425
 Desiccated thyroid, high-risk medication, 108
 Desipramine, 135, 355, 385, 427, 429, 434
 Desmopressin, 239
 Dessicated thyroid, 262, 277
 Desvenlafaxine, 384
 Detrusor muscle, 221, 229–230
 Detrusor overactivity, 231, 232, 236–237
 Dexamethasone, 205, 306
 in hospice and palliative care, 136
 terminally ill and, 133
 Dexbrompheniramine, high-risk medication, 107
 Dextranomer/hyaluronic acid, 311
 Dextroamphetamine, 138
 Dextromethorphan, 142, 295
 DiaBeta, 261
 Diabetes mellitus, 258–274
 case, 284–285
 complications related to, 270–271
 glycemic control in, 225–225
 hepatitis B vaccine and, 506
 individualized treatment for, 263
 pharmacotherapy options for, 261–262, 264–265
 type 1½, 259
 Diabetes Prevention Program, 272
 Diabinese, 261
Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 335, 345, 379, 385, 393, 397–398
 Diagnostic testing, 521
 DIAPPER, 230
 Diarrhea, 312–315
 Diastolic dysfunction, 159, 167, 173
 Diazepam, 402
 Diclofenac gel, 445
 Dietitians, 8
 Digital rectal examination (DRE), 496
 Digitalis, toxicity, 295
 Digoxin, 160, 175
 toxicity of, 157, 175–176, 180
 dementia and, 335
 diarrhea and, 312
 functional decline and, 66–67
 heart failure and, 173, 174, 175
 kidney disease and, 176
 ventricular rate control and, 178
 volume of distribution and, 68
 withdrawal of, 131
 Digoxin >0.125 mg/day, high-risk medication, 107
 Digoxin Investigation Group, 175

- Diltiazem, 178
 Dipeptidyl peptidase IV inhibitors, 263, 264, 268
 Diphenhydramine, 395
 Diphenhydramine (oral), high-risk medication, 107
 Diphenoxylate/atropine, 301, 312
 Diphtheria, 491–492
 Dipyridamole, oral short-acting, high-risk medication, 107
 Direct vasodilators, 71
 Disclosure of information, 33
 Disease modifying anti-rheumatic drugs (DMARDs), 456–458
 Disopyramide, high-risk medication, 107
 Distribution, age-related changes in, 68–69
 Disulfiram, 401
 Diuretics, 528
 - dry mouth and, 294–295
 - dysphagia and, 297
 - heart failure and, 173, 174
 - insomnia and, 381
 - pharmacodynamic changes, recommendations for, 71
 - renal/urologic disorders and, 222, 225, 227, 230, 235, 243, 252
 - withdrawal of, 131
 Divalproex sodium, altered taste and, 295
 Diverticular disease, 307–308
 Diverticulitis, 307
 Diverticulosis, 307
 DNR (Do not resuscitate), 29, 38, 39–40
 Dobutamine, dyspnea and, 142
 Documentation, hospital vs. long-term care facility, 25
 Docusate, 301, 309
 Dofetilide, 178, 180
 Dolasetron, 306
 Domperidone, 305
 Donepezil, 340, 341, 355
 Dopamine agents, 352
 Dopamine agonists
 - orthostatic hypotension and, 159
 - pharmacodynamic changes, recommendations for, 71
 Dopamine antagonists, 305, 339
 Dorzolamide, 420
 Dosage forms, palliative care and, 129
 “Doughnut hole,” 45, 181
 Doxazosin, 234, 237, 244, 245–246
 Doxepin, 394–395, 426
 Doxepin topical, 129
 Doxylamine, 395
 - as high risk medication, 107
 Driving assessment, 96
 Dronabinol, 319
 - anorexia and, 141
 - in hospice and palliative care, 137
 Droperidol, 305
 Drug discount programs, 83
 Drug Regimen Unassisted Grading Scale (DRUGS), 84
 Drug-disease interactions, 107–108
 Drug-resistant *S. pneumoniae*, 529, 530
 Drusen, 417, 421
 Dry eye, 420–422
 Dry mouth, 293, 294–295
 Dry-powder inhalers, 209–210
 Dual energy x-ray absorptiometry (DEXA) scan, 82, 448, 453, 455, 458
 Duloxetine, 135, 233–235, 364, 384, 389–390, 426–427, 429
 Duloxetine hydrochloride, 233
 Durable power of attorney for healthcare, 38
 Dutasteride, 234, 245, 246, 252, 501
 Dying, 124–125
 Dysgeusia, 139, 293–294
 Dyskinesias, 334, 349, 351
 Dyslipidemia, 158, 166–167, 260, 263, 274
 Dysphagia, 294–295, 297–302
 - case, 323–324
 Dyspnea, 141–142
 Dysuria, 528
-
- E**
E. coli, 527, 529
 Early-onset alcoholism/abuse/dependence, 378, 396
 EASE Tool, 144
 Eden Alternative, 12
 Edmonton Symptom Assessment Scale, 128
 Eisenhower, Christine, 257–292
 ELATE trial, 187
 Elder abuse, 41
 Electroconvulsive therapy, 383
 Electrolytes, 400
 Elimination, 129
 - age-related changes in, 70
 - volume of distribution and, 69
 Emergency department care, 12, 13
 - case, biomedical principles, 72–73
 Endocrine changes, 60–61
 Endocrine disorders, 257–258
 - diabetes mellitus, 258–274
 - menopause, 278–279
 - pituitary gland dysfunction, 278
 - sex hormone changes, 278
 - sexual dysfunction, 279–282
 - sexual dysfunction medications, 263
 - thyroid disease, 274–278
 - thyroid disorders medications, 262
 - treatments and considerations, 261–262
 - weight loss/control, 260, 262–265, 267, 272–275
 End-of-life care, 125–126
 - decisions for, 39

- discussion of, 127
 medication appropriateness in, 129–130
 optimizing medications in, 130–131
 pharmacologic management of symptoms in, 131–133
- Ends-based thinking, 32
- End-stage renal disease (ESRD), 44, 222
- Enoxaparin, 168
 intracranial hemorrhage and, 169
 venous thromboembolism and, 187
- Ensure, 319
- Entacapone, 350, 353
- Enterobacter* sp, 525
- Enterobacteriaceae*, 299, 531
- Enterococci, 518
- Ephedrine, 364
- Epilepsy, 334–335, 355
- Epoetin-alfa, 487
- Epogen, 487
- Eptifibatide, 169
- Erectile dysfunction, 263, 279–282
- Ergot mesylates, high-risk medication, 107
- Erythropoiesis, 479, 481
- Erythropoietic-stimulating agents, 486–487
- Erythropoietin, 479, 481–482, 484
- Erythropoietin analogues, diarrhea and, 312
- Escitalopram, 138, 389
- Esomeprazole, 312
- Esophageal dysphagia, 297
- Estazolam, 394
- Esterified estrogen, high-risk medication, 108
- Estradiol vaginal insert, 234
- Estradiol, high-risk medication, 108
- Estrogen and bazedoxifene, 449
- Estrogen cream, 527
- Estrogen and progesterone, 233
- Estrogen and progestin, 278, 279
- Estrogen therapy, 233, 263, 278, 281–282
- Estropipate, high-risk medication, 108
- Estus, Erica L., 221–256
- Eszopiclone, 108, 394
- Etanercept, tuberculosis and, 213
- Ethambutol, 214
- Ethanol withdrawal, 398–399
- Ethics
 biomedical ethics and, 30–32
 community pharmacy case, 52–53
 considerations in, 29–30
 decision making, 32
 skilled nursing facility case, 49–50, 50–51
- ETHNIC(S) assessment, 35, 36
- Ethnogeriatrics, 29, 34–35
- European Association of Urology, 233
- European Prospective Investigation into Cancer and Nutrition, 500
- European Society of Hypertension/European Society of Cardiology, 162
- European/Australian Stroke Prevention in Reversible Ischaemia Trial, 183
- Euthyroid sick syndrome, 273, 276–278
- Evidence-based strategies, application of, 4, 5
- Exelon, 340
- Exemestane, 499
- Exenatide, 261, 267
- Exercise, 260, 263, 273, 274, 442, 444, 446
- EXIT-25, 95
- Eye changes, 419
- Eye drops, 423, 434
- Ezogabine, 363
 drug-disease interactions with, 365, 366
 seizures and, 358

F

- FACES rating scale, 83
- Faith-based lifestyle, 35
- Falls, 64, 93, 440–443
 rates/related injuries, 6
 risk factors for, 441
- Farxiga, 262
- Fatigue, 141, 260, 271, 277
- Fecal impaction, 293, 309–311
- Fecal incontinence, 311–313
- Federation of State Medical Boards Model Policy for Use of Controlled Substances for the Treatment of Pain, 402
- Fee-for-service pharmacy services, 16–17
- Felbamate, 365, 358
- Felty syndrome, 456–457
- Fentanyl, 228, 430
- Fentanyl transdermal patches
 absorption and, 68
 in hospice and palliative care, 134
- Ferritin, 479, 483
- Ferrous sulfate, 310
- Fesoterodine, 236
- Fever, 518, 519
- Fiber, 310, 500
- Fibrinolytic therapy, 157, 168–170
- Fidaxomicin, 314
- Finasteride, 234, 245–246, 252, 501
- 5-alpha reductase inhibitors, 243–244, 243–245, 252, 501
- 5-fluorouracil, 486
- 5-HT₃ receptor antagonists, 305–306
- Five Wishes™, 38
- Flecainide, atrial fibrillation and, 178
- Fluconazole, 295
- Fludrocortisones, 159–160, 354
- Fluid and electrolyte disorders, 226–227
- Flunisolide, 203
- Fluoroquinolone-resistant *S. aureus*, 518
- Fluoroquinolones, 301, 364, 523, 527, 530

- Fluoxetine, 353, 383–384
 Fluticasone and salmeterol, 204
 Fluticasone and vilanterol, 204
 Fluticasone propionate, 203, 208–209
 Fluvastatin, intensity, 179
 Fluvoxamine, 353, 364
 Foam dressing, 462, 465
 Folate, 400
 Folate-deficiency anemia, 482–484, 486
 Fondaparinux, 168
 - deep-vein thrombosis and, 185–186
 - venous thromboembolism and, 187
 Food and Drug Administration (FDA), 167, 208, 233, 236, 314
 - acetaminophen and liver toxicity, 430
 - Adverse Event Reporting System, 213
 - citalopram warning, 383
 - clinical trial data, 4
 - ESAs and, 487
 - fluoroquinolones and tendon rupture, 527
 - Medicare Part D drugs, 46
 - opioid requirements, 402
 - testosterone safety and, 280
 Formoterol, 204
 Formulary management, 25
 Fosphenytoin, 362
 - drug-disease interactions and, 365
 - seizures and, 358
 Fracture risk assessment (FRAX), 81, 448, 453, 455, 472
 Fractures, 447–455
 - case, 467–469
 Frailty, 57, 67
 Frailty Index, 517
 Friction, 439, 461, 462
 Fritsch, Michelle A., 439–478
 Frontal Assessment Battery, 95
 Frontotemporal dementia, 339, 342
 Functional assessment, 92–94
 Functional Assessment Screening (FAST) scale, 93
 Functional Assessment Staging Test, 128
 Functional decline, 57, 66–67
 Functional incontinence, 231, 234
 Functional status, 5–6
 Furosemide, 218, 312, 540
 Futility of treatment, 40
-
- G**
- Gabapentin, 357, 362, 427, 429–430
 - drug-disease interactions by, 365–366
 - in hospice and palliative care, 135
 - seizures and, 358
 Gail risk score, 499
 Gait, 93
 Galantamine, 340, 341
 Gastroesophageal reflux disease, 302–304, 325
 Gastrointestinal changes, 62
 Gastrointestinal disorders, 293
 GDS. *See* Geriatric Depression Scale
 Generalized anxiety disorder (GAD), 385–386, 389
 Generalized seizures, 356
 Genitourinary changes, 60
 Gentamicin, 523
 Geriatric, 3
 Geriatric assessment, 77–78
 - ambulatory case, 97–98
 - atypical disease presentation and, 100
 - cognitive assessment, 84–89
 - functional assessment, 92–94
 - laboratory measurements, 82
 - long-term care setting reassessment, 99
 - medical problems, medications review, 83–84
 - medication therapy management and, 100
 - neuropsychiatric assessment, 89–92
 - patients incapable of self-reporting and, 82–83
 - physical assessment, 78–82
 - social assessment, 94–97
 - team for, 8
 Geriatric care challenges, 3–5
 - caregiver burden, 17–20
 - clinical literature subgroup perspective case, 21–22
 - elderly subpopulations, 5–7
 - formulary management, 25
 - healthcare workforce demographics, 9–10
 - hospital vs. LTCF documentation, 25
 - multiple care venues, 7–17
 - multiple venues/caregivers coordination of care case, 23–24
 Geriatric Depression Scale (GDS), 77, 89–91, 128, 379
 Geriatric population, 4, 26
 - subpopulations in literature, 6–7
 - subpopulations of, 5–6
 Geriatric psychiatry, 7
 Geriatric syndromes, 64
 Geriatrician, 3, 7, 9
 Geriatrics Cultural Navigator, 37
 Gerontological nurse, 3, 7, 9
 Giant cell arthritis, 459–461
 Ginkgo biloba, 113, 364
 Ginseng, 364
 Glaucoma, 418–419, 421–423
 Gleason grade, 501
 Glimepiride, 224
 Glimepiride, 261, 265
 Glipizide, 224, 261, 265–266
 Global Initiative for COPD, 201
 Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), 263, 267–268
 Glucerna, 319

GLUCOCARD Expression, 270
 Glucocorticoid injections, 444, 445
 Glucocorticoid therapy, 209, 447, 455–461, 466
 Glucophage, 261
 Glucosamine, 445
 Glucotrol, 261
 Glyburide, 261, 265, 272
 as high-risk medication, 107, 108
 Glycopyrrolate, 137
 Glyset, 261
 Goals of care, 130, 131
 Golytely, 495
 Goserelin, 455
 Gram-negative enteric bacilli, 529
 Granisetron, 305, 306
 Graves' disease, 257, 275
 Greatest Generation, 35–36
 Green House, 12
 Grief, 144
 Growth hormone (GH), 57, 61–62, 65, 258, 378
 Guanabenz, high-risk medication, 107
 Guanfacine, high-risk medication, 107
 Guillain-Barré syndrome, 490

H

H₂ antagonists, 447
 H₂ blockers, 118
 dementia and, 335
 drug-disease interactions, 108
 H2RAs, diarrhea and, 313
 Hajjar, Emily R., 105–121
 Haloperidol, 348
 anxiety and, 138
 delirium and, 143
 in hospice and palliative care, 136
 Hamilton rating scale for anxiety (HRSA), 378, 389
 Handwashing, 313–314
 Hanlon, Joseph T., 105–121
 HAS-BLED score, 181
 Health and Human Services, Department of, 12
 Health Foundation for Western and Central New York, 443
 Health Information Portability and Accountability Act (HIPAA), 34
 Health insurance programs, 45
 Health literacy assessment, 83–84
 Health maintenance organizations, 44
 Health status, 5–6
 Healthcare financing, 44–45, 47–48
 Healthcare workforce, 9–10
 Healthy People 2020, 449, 463, 490
 Hearing changes, 63
 Hearing impairment, 418–424
 Heart and Estrogen/Progestin Replacement Study, 233

Heart failure, 172–177, 193
 Heart Failure Society of America, 173, 174
Helicobacter pylori, 493
 Hematology changes, 63
 Hematopoietic, 479, 481
 Hemoglobin A_{1c} (HbA_{1c}), 257, 258, 260, 263
 Hemp seed, 310
 Hepatitis B immunization/vaccine, 458, 506
 Hepcidin, 479, 482, 484
 Herpes zoster, 492
 Herpes zoster vaccine, 489, 492–493
 High-risk medications, 107–108
 Hispanic culture, 39
 Histamine antagonists, nausea and vomiting, 139
 Histamine H₂ blockers, 68
 Histamine-2 receptor antagonists, 303
 Hix, Meri, 417–438
 HMG-CoA reductase inhibitor, 225
 HMOs, 47
 "Holiday heart" syndrome, 177
 Home health agencies, 10
 Home health aide costs, 13
 Home-based care, 10–11
 Hormone changes, 60–62
 Hormone therapy (HT), 65, 184, 257, 278–279, 421
 Hospice care, 40–41, 123–124, 126, 149
 case, 147–148
 death/dying, 124–125
 end-of-life, 125–126
 pharmacologic management of symptoms, 131–144
 tailoring medication appropriateness in, 129–130
 Hospital environments, 12–13
 Hume, Anne L., 257–292
 Humoral, 480–482
 Hutchison, Lisa C., 57–76, 123–154, 293–332, 333–376
 Hyaluronic acid injections, 445–446
 Hydralazine
 depression and, 381
 diarrhea and, 312
 dyspnea and, 142
 orthostatic hypotension and, 159
 Hydralazine/nitrate, heart failure and, 173, 174
 Hydrocodone, 142
 Hydrocodone/acetaminophen, 134
 Hydrocolloids, 313, 462, 464
 Hydrogels, 462, 464
 Hydromorphone, 134
 Hydrophilic fibers, 462, 465
 Hydroxychloroquine, 457
 Hydroxyurea, 486
 Hydroxyzine, high-risk medication, 107
 Hyoscyamine, 137
 Hyperglycemia, 111, 259, 260, 263, 272, 288

Hyperosmolar hyperglycemic nonketotic syndrome, 272
 Hypertension, 159, 160–163, 193, 224
 Hypertension in Very Elderly Trail (HYVET), 162
 Hyperthyroidism, 274–278
 Hypertonic dressing, 465
 Hypnotic agent, 394
 Hypodermoclysis, 334, 347
 Hypoglycemia, 263, 266–267, 271–272
 Hypomagnesemia, 228
 Hyponatremia, 227–228
 case, 250–251
 Hypothyroidism, 273–278
 case, 286–287

I

IADL. *See* Instrumental activities of daily living, 77
 Ibandronate, 449, 451
 Ibuprofen, 113, 134, 228
 Ibutilide, atrial fibrillation and, 178
 iGeriatrics smartphone app, 37
 Imipenem, 523
 Imipramine, 233, 426
 as high-risk medication, 107
 Immobility complications, 13
 Immunizations, 458, 488–492
 case, 504–505
 history, 83
 Immunology changes, 63
 Immunosenescence, 199, 212
 Immunosuppressants, dosing of, 71
 Inappropriate medications, 105–108, 130–131
 InCHIANTI study, 484
 Incretin mimetics, 264
 Independence, 95
 Indomethacin, high-risk medication, 108
 Indwelling catheters, 522, 527–528
 Infection, 516–521
 Infection surveillance, 520
 Infectious Diseases Society of America, 212, 519–521, 525–526, 529, 531
 Infective endocarditis, 295
 Inflammaging, 516
 Inflammatory markers, 484
 Infliximab, 213
 Infliximab plus methotrexate, 457
 Influenza, 516–517, 532–535
 case, 538–539
 outbreak, 515, 533–534
 Influenza immunization/vaccine, 32, 110, 458, 488–490
 Informal caregiver, 4, 10, 18, 19
 Informed consent, 30, 33–34
 INH therapy, 213–214
 Inhaled anticholinergics, 200, 211
 Inhaled anti-inflammatory, 203, 205
 Inhaled beta agonists, 200, 208, 211
 Inhaled bronchodilator, 202, 204
 Inhaled bronchodilator and steroid, 204
 Inhaled corticosteroids, 201, 203–207
 altered taste and, 295
 oral thrush and, 295
 Inhaled long-acting bronchodilator/steroid, 110
 Inhaled medications, 295
 Inotropic agents, 142
 Insoluble fiber diet, 307
 Insomnia, 392–396, 407
 case, 405–406
 Institute for Health Care Improvement, 463
 Institute of Medicine (IOM), 9, 17, 319, 453–454
 Instrumental activities of daily living (IADLs), 77, 92–93
 Insulin, 224, 260–261, 265–274, 364
 adverse drug withdrawal events and, 112
 elimination and, 70
 Insulin glargine, 266
 Insulin lispro, 266
 Insulin pens, 266–267
 Insurance coverage, 95
 Interferon
 diarrhea and, 312
 hypothyroidism and, 275
 Interferon alfa, 295
 Interleukin-6, 482
 Intermittent claudication (IC), 158, 171–172
 International Consultation on Incontinence
 Management of Fecal Incontinence, 312
 International League Against Epilepsy, 356, 360
 International Menopause Society, 279
 International Prostate Symptom Scores, 246
 Interpersonal psychotherapy, 378, 382
 Interprofessional team, 4, 8, 16–17
 Intrinsic factor, 480, 483
 Invokana, 262
 Ipratropium, 142, 202, 211, 218, 540
 Ipratropium bromide, 202, 211
 Iron, 277, 310
 Iron sulfate, 485
 Iron supplements, 303, 485–486
 Iron supplements, GERD and, 303
 Iron-deficiency anemia, 482, 483, 485–486, 488
 Ischemic stroke, 158, 165, 177, 182
 Islam, 37
 Isoniazid, 213–214, 364
 Isoniazid and rifapentine, 213
 Isonicotinic acids, 214
 Isosorbide dinitrate, 142
 Isoxsuprine, high-risk medication, 107
 IST trial, 184

J

Januvia, 261
 Japanese culture, 35
 Joint Commission, The, 113, 441, 449
 Joint National Committee (JNC)
 VII, 160–163
 VIII, 161–163, 225
 Judaism, 37
 JUPITER study, 166
 Justice, 30, 32

K

K. pneumoniae, 529
 Katz ADL tool, 92
 Kava kava, 364
 Kegel exercises, 221, 233
 Ketorolac, oral and parenteral, high-risk medication,
 108
 Kidney Disease Improving Global Outcomes, 487
 Kidney Disease Outcomes Quality Initiative, 225
 Klebsiella with extended spectrum beta lactam
 phenotypes, 518
 Korsakoff syndrome, 397

L

Labile hypertension, 161
 Laboratory evaluation, 82–84
 Laboratory measurements, 82
 Lacosamide, 358, 363, 365
 Lactic acidosis, 265
Lactobacillus, 310, 315
 Lactulose, 133, 309–310, 312
 Lam, Sum, 479–513
 Lamivudine, 486
 Lamotrigine, 357–358, 360, 363, 370
 drug-disease interactions, 365, 366
 seizures and, 358, 360
 Latanoprost, 420, 422
 Late-life anxiety, 378, 385–386
 Late-life depression, 378, 379–380, 382, 385
 Late-life substance use disorder, 378, 396
 Latent tuberculosis infection (LTBI), 212, 213
 Late-onset alcoholism/abuse/dependence, 378,
 396–397
 Late-onset depression, 378, 379
 Lawton IADL, 93
 Laxative abuse, 293, 311
 Laxatives, 110, 133, 309–310, 312
 Leflunomide, 457
 Left ventricular dysfunction, 178.
 Left ventricular function, 158, 173, 193

Left ventricular systolic dysfunction, 174
 Legal capacity, 39
 Legal-assisted suicide, 40
 Length of life decisions, 39
 Lennox-Gastaut, 363
 Leukotriene modifiers, 205
 Leukotriene receptor modifiers, 201
 Leuprolide, 455
 Levodopa, 301
 Levalbuterol, 211
 Levalbuterol hydrochloride, 202
 Levalbuterol tartrate, 202
 Levetiracetam, 363, 370
 drug-disease interactions, 365
 seizures and, 358, 360
 Levitra, 263
 Levodopa, 350
 orthostatic hypotension and, 159
 prescribing cascade and, 114
 Levodopa/carbidopa, 112, 349, 350–353, 370
 Levofloxacin, 523
 Levothyroxine, 262, 276–277
 Lewy Body dementia, 159, 334, 338
 Lidocaine patch, 129, 135
 Lidocaine topical, 426–428
 Life care communities, 11
 Life-sustaining treatments, 39
 Likert scale measure, 112
 Linagliptin, 268
 Linnebur, Sunny A., 77–103
 Liotrix, 262
 Lipid management, 165–167
 Lipophilic medications, distribution and, 69
 Liraglutide, 267
 Lithium, 301, 364, 382–383
 altered taste and, 295
 hypothyroidism and, 275–276
 Living will, 30, 38
 Living/care environment, 5, 6
 Loading first dose, 520
 Loeb criteria, 525, 528
 Long-acting beta agonists (LABA), 202–204, 208,
 211
 Long-term acute care, 12–13
 Long-term care costs, 13
 Long-term care facility (LTCF), 4, 8, 10–12, 520
 tuberculosis and, 212–213
 Long-term care pharmacies, 16–17, 46
 Loop diuretics, 164
 aging kidney and, 222
 dehydration and, 252
 functional decline and, 66
 hearing loss and, 63
 orthostatic hypotension and, 159
 Loperamide, 312
 Lorazepam, 71, 390, 392, 400, 402, 407

anxiety and, 138
 dyspnea and, 142
 in hospice and palliative care, 136
 as palliative sedation, 144
 Lorcasein, 262, 273–274
 Lovastatin, intensity, 179
 Low molecular weight heparin, 169
 deep-vein thrombosis and, 185
 venous thromboembolism and, 186–187
 Low-dose helical computed tomography (LDCT),
 496–497
 Lower urinary tract symptoms (LUTS), 239–246
 Lubiprostone, 309
 Lung cancer
 chemoprevention, 500
 screening, 496–497
 Lutein, 422, 423
 Lycopene, 501

M

Ma huang, 364
 Macrolide plus beta lactam, 530
 Macrolide-resistant *S. pneumoniae*, 530
 Macrolides, 312
 Macronutrients, 319, 320
 Macrophage migration inhibitory factor, 482
 Macrovascular complications, 257, 259, 268
 Macular degeneration, 418, 421–424
 Magic Cup, 319
 Magnesium hydroxide, 309, 310, 311
 Magnesium-containing antacids, diarrhea and, 312
 Maher, Jr., Robert M., 105–121
 Mail-order pharmacies, 10
 Maintenance of sinus rhythm, 178
 Malnutrition, 79, 298
 Mammography, 494–495
 Managed care, 30, 47, 54
 Manufacturer patient assistance programs, 83
 Maprotiline, 364
 Marijuana, orthostatic hypotension and, 159
 Markov decision analysis, 454, 472
 Mast cell stabilizers, 205
 MATCH trial, 183
 Mathys, Monica, 377–416
 McGeer criteria, 522, 525, 528
 Meal replacements/supplements, 317, 319
 Mechanically altered diet, 299
 Medicaid, 16, 45–46
 beds availability, 13–14
 CMS and, 44
 dental work and, 297
 end-of-life care and, 126
 long-term care facility and, 12
 medication assessment and, 83
 nursing home residents and, 42
 PACE and, 11
 transportation and, 96
 waivers, 19
 Medical history, 83
 Medical nutrition therapy (MNT), 260
 Medicare, 316
 age eligibility, 4
 CMS and, 44
 coverage assessment, 95
 dental work and, 297
 diabetes test strips and, 269–270
 hospice and, 126
 laboratory measurements and, 82
 last year of life and, 48
 long-term care facility and, 12
 MTM and, 84
 nursing home residents and, 42
 OASIS and, 92
 PACE and, 11
 peripheral arterial disease and, 170
 skilled nursing care, 12, 13
 supplement, 45
 warfarin and point-of-care testing, 187
 Medicare Advantage, 44, 45
 inappropriate medications and, 130
 Medicare Modernization Act (MMA), 44, 46
 Medicare Part A, 44, 45
 Medicare Part B, 44, 45
 Medicare Part C. *See* Medicare Advantage
 Medicare Part D, 16, 44–47
 coverage gap, 455
 formulary, 113, 118
 formulary adherence, 83
 doughnut hole gap, 96
 end-of-life care and, 126
 MTM and, 114
 new anticoagulants and, 181
 Medicare Prescription Drug Coverage. *See* Medicare
 Part D
 Medicare supplement, 45
 Medication
 absorption, 68–69
 access, 15–16
 adherence, 35–36, 300, 454–455
 appropriateness, 129–130
 assessment, 83, 114
 distribution, 68–69
 history, 118
 reconciliation, 113–118
 review, 15
 self-administration, 6
 sensitivity, 68–69
 Medication Appropriateness Index (MAI), 109
 Medication Management Instrument for Deficiencies
 in the Elderly (MedMalDE™), 84
 Medication therapy management (MTM), 4, 46,
 84–85, 95, 114–115, 223

- Medroxyprogesterone, 278
 Megacolon, 293, 313, 315
 Megestrol, high-risk medication, 107–108
 Megestrol acetate, 319
 anorexia and, 139, 141
 in hospice and palliative care, 137
 Meglitinides, 264, 267, 270
 Melatonin
 delirium and, 347
 replacement, 395
 Memantine, 19, 184, 340–342, 344, 356, 364, 370
 Memory loss, 167
 Menopause, 61, 63, 278–279
 Mental capacity, 39
 Meperidine, 364, 430
 as high-risk medication, 108
 Mephobarbital, high-risk medication, 107
 Meprobamate, high-risk medication, 108
 Meropenem, 523
 Mesalamine, 308
 Mesalazine, 307
 Metabolism, age-related changes, 69
 Metaxalone, high-risk medication, 108
 Metered-dose inhalers, 209, 210
 Metformin, 224–225, 260–261, 263–266, 274, 312, 486
 Methadone, 134, 427, 430
 Methenamine, 525
 Methicillin-resistant *Staphylococcus aureus* (MRSA)
 518, 530
 Methimazole, 262, 275, 276–277
 Methocarbamol, high-risk medication, 108
 Methotrexate, 457, 458, 460, 486
 Methoxypolyethylene glycol-epoetin beta, 487
 Methylcellulose, 298, 311
 Methylidopa, high-risk medication, 107
 Methylnaltrexone, 133, 309
 Methylphenidate
 depression and, 138
 fatigue and, 141
 in hospice and palliative care, 137
 Methylprednisolone, 205, 460
 Methylsulfonylmethane (MSM), 445
 Methylxanthine, 204
 Metoclopramide, 305, 364
 adverse drug withdrawal events and, 112
 anorexia and, 141
 diarrhea and, 312
 functional decline and, 66
 in hospice and palliative care, 137
 nausea/vomiting and, 140, 305
 prescribing cascade and, 114
 Metoprolol, 71, 112
 Metoprolol XL, 173–174, 176
 Metronidazole, 67, 307, 314, 315
 Metronidazole plus cefepime, 523
 Metronidazole plus ceftazidime, 523
 Metronidazole plus imipenem, 523
 Metronidazole plus meropenem, 523
 Microalbuminuria, 258, 271
 Microbiologic culture, 518
 Micronase, 261
 Microvascular complications, 258, 268
 Micturition, 221, 229–230, 246
 Midazolam
 in hospice and palliative care, 136
 palliative sedation and, 144
 Midodrine, 159, 160
 Miglitol, 259, 265
 Mild cognitive impairment, 335
 Miller, Susan W., 29–56
 Milrinone, 142
 Mineral dietary intakes, 320
 Mini-Cog, 84, 85, 86–87
 Mini-Mental State Examination (MMSE), 77, 84, 85, 88, 210, 337, 341
 Minimum Data Set (MDS), 519–520
 Mini-Nutritional Assessment, 317, 318–319
 Minor depressive disorder, 379–380
 Minoxidil, 159
 Mirabegron, 234, 236, 237
 Mircera, 487
 Mirtazapine, 319, 381–382, 384, 389, 395
 anorexia and, 141
 depression and, 138
 in hospice and palliative care, 136
 Misoprostol, 110, 312
 Mixed incontinence, 231–232, 234
 MMSE. *See* Mini-Mental State Examination
 Modafinil, 354
 Modification of Diet in Renal Disease (MDRD), 70, 223
 Modified British Medical Research Council questionnaire, 201
 MOLST (Medical Orders for Life-Sustaining Treatment), 38
 Mometasone furoate, 203
 Monoclonal antibody, 206
 Monsky Scale, 84
 Montelukast, 205
 Montreal Cognitive Assessment (MoCA), 85, 89
 Morphine, 429
 metabolism of, 69
 STEM1, NSTEMI, and, 168
 Morphine extended release, 134
 Morphine immediate release, 133–134
 Morphine sustained release, 133
 Motor complications, 334, 349
 Motor function, 6
 Motor symptoms, 334, 349
 Movement Disorder Society, 355
 Moxifloxacin, 523

MTOPS study, 246
 Mucosal anesthetics, 297
 Multi-Dimensional Health Assessment Questionnaire, 457
 Multiple care venues, 14
 Multiple co-morbidities, 5
 Multiple venues, coordination of care case, 23–24
 Multivitamins, 113, 301
 Muscarinic antagonists, 235
 Muscle relaxants, 184, 243
 delirium and, 345
 dry mouth and, 294
 Musculoskeletal assessment, 81
 Musculoskeletal changes, 62
 Musculoskeletal pain, 426
 Myelodysplasia, 480, 484–485

N

Nabilone, anorexia, 141
 Naltrexone, 401
 Namenda, 340
 Naproxen, 135
 Narcotic analgesics, 528
 Nateglinide, 261, 267
 National Cancer Institute Surveillance, Epidemiology, and End Results Program, 493
 National Committee for Quality Assurance (NCQA)
 drug-disease interactions, 108
 high-risk medications, 107–108
 National Comorbidity Survey, 386
 National Family Caregiver Support Program, 19
 National Health and Nutrition Examination Survey (NHANES III), 227, 277, 453, 480, 482, 484
 National Institute of Neurologic and Communicative Disorders, 337
 National Institute of Neurological Disorders and Stroke (NINDS), 183–184
 National Institute on Alcohol Abuse and Alcoholism, 397
 National Kidney Foundation, 222, 224
 National Lung Screening Trial (NLST), 496–497
 National Osteoporosis Foundation, 449
 National Patient Safety Program, 441
 National Pressure Ulcer Advisory Panel, 461–462, 463
 Native American culture, 35
 Nausea, 138–140, 304–306
 Nawarskas, James J., 479–513
 Nebivolol, 174
 Nebulized morphine, dyspnea, 142
 Nebulizer, 199, 210, 218
 Nedocromil sodium, 205
 Neglect, elderly, 41
 Neomycin, 492
 Nephropathy, 271
 Neuraminidase inhibitors, 532
 Neurogenic bladder, 221, 232
 Neuroleptic sensitivity, 334, 338
 Neurologic assessment, 81–82
 Neuropathic pain, 418, 424–425
 treatments, 427
 Neuropsychiatric assessment, 89–92
 Neuropsychiatric Inventory (NPI), 91
 Neuropsychiatric Questionnaire, 341
 Neuropsychiatric symptoms, 334, 342–343
 Neurosyphilis, 339
 Neurotoxicity, 429
 Neutral protamine Hagedorn (NPH) insulin, 266
 New York Heart Association Functional Classification, 128, 172, 458
 Newest Vital Sign (NVS), 83
 Nicotine, insomnia and, 381
 Nifedipine, immediate release, high-risk medication, 107
 Nitazoxanide, 314
 Nitrates, 281–282, 301
 angina and, 133
 hypertension and, 163
 orthostatic hypotension and, 159
 Nitrofurantoin, 523, 525–526
 as high-risk medication, 107
 Nitrofurantoin macrocrystals, high-risk medication, 107
 Nitrofurantoin monohydrate/macrocrystals, high-risk medication, 107
 Nitroglycerin, IV, STEMI, NSTEMI and, 168
 Nitroglycerin, sublingual, STEMI and, 168
 NMDA receptor antagonist, 340
 N-methyl D-aspartate (NMDA)
 receptor antagonist, 340
 topical antagonists, 129
 Nociceptive pain, 424, 425
 Nociceptors, 418, 424
 Nonadherent sheets, 464
 Nonbenzodiazepine hypnotics, 108
 Nonmaleficence, 30, 32, 40
 Nonmotor symptoms/complications, 334, 349
 Non-ST-Elevation Myocardial Infarction (NSTEMI), 168–169
 Nonsteroidal anti-inflammatory agents (NSAIDs), 128, 176–177, 225, 296
 bleeding and, 180
 dementia and, 335
 diarrhea and, 312
 diverticular disease and, 307–308
 drug-disease interactions, 108
 dysphagia and, 297
 gastrointestinal hemorrhage and, 71
 GERD and, 303, 304
 heart failure and, 173
 musculoskeletal/connective tissue disorders and, 444–446, 457, 460–461

pain/sensory disorders and, 419, 425–426, 429–430
 terminally ill and, 133
 topical, 445, 446
 Normal pressure hydrocephalus, 339
 Normeperidine, 430
 Norton scale, 461
 Nortriptyline, 135, 355, 385, 427, 429, 434
 NPI-NH (Neuropsychiatric Inventory for Nursing Homes), 91
 NPI-Q (Neuropsychiatric Inventory Questionnaire), 77, 91
 NSAIDs. *See* Nonsteroidal anti-inflammatory drugs
 Numeric Rating Scale, 83
 Nurse practitioners, 10
 Nursing Home Reform Law, 42, 43
 Nursing Home Resident's Bill of Rights, 42, 43
 Nursing homes, decision-making and, 41–42
 Nutraceutical, 439, 445
 Nutrient-deficiency anemia, 482
 Nutrition, 315–320
 Nutritional supplements, 184
 Nystatin, 295

O

O'Connell, Mary Beth, 439–478
 Obesity, 79, 272–273, 316–317
 Obesity Society, 272–274
 Obsessive-compulsive disorder, 385, 388
 Occupational therapists, 8, 10
 Octreotide, 312
 Off, 334, 351, 352
 Olanzapine, 143, 338, 344, 348
 “Old-old,” 5
 Omalizumab, 201, 206
 Omega-3 fatty acid supplementation, 421, 422–423
 Omeprazole, altered taste and, 295
 On, 334, 349, 352
 OnabotulinumtoxinA, 234, 236–237
 Ondansetron, 305, 306, 354
 Onglyza, 261
 Ophthalmic assessment, 79–80
 Opiates, 243, 304, 307, 309–310
 Opioid abuse, 402
 Opioids, 301
 adverse drug reactions and, 111
 adverse effects of, 447
 constipation and, 459
 delirium and, 347
 dementia and, 335
 depression and, 381
 dying patient and, 132, 133
 dyspnea and, 142
 functional decline and, 66
 musculoskeletal/connective tissue disorders and, 446, 466

pain/sensory disorders and, 425–427, 430
 pharmacodynamic changes, recommendations for, 71
 urinary tract functions and, 230
 Oral anti-inflammatory, 205
 Oral assessment, 80
 Oral bronchodilators, 202, 204
 Oral health, 294–295, 295
 Orange juice with iron, 485
 Orinase, 261
 Orlistat, 262, 273–274, 312
 Oropharyngeal dysphagia, 293, 297
 Orphenadrine, high-risk medication, 108
 Orthostasis, 352
 Orthostatic hypotension, 158–161, 191–192
 Oseltamivir, 490, 532, 534
 Osmotic agents, 309
 Ospemifene, 263, 281, 282
 Osphena, 263
 Osteoarthritis, 443–447
 Osteopathic geriatrics, 7
 Osteoporosis, 441, 447–455
 case, 467–469
 pharmacotherapy, 450–452
 Otosopic assessment, 80
 Outcome and Assessment Information Set (OASIS), 92
 Outpatient Bleeding Risk Index, 180
 Overactive bladder, 231–235, 243–245
 Overflow incontinence, 230–232, 234, 237, 238
 Overnutrition, 316
 Over-the-counter agents/medications, 46, 118
 Owens, Norma J., 221–256
 Oxazepam, 390, 392, 400, 402, 407
 anxiety and, 138
 In hospice and palliative care, 136
 use of, 71
 Oxcarbazepine, 357, 360, 362, 370
 drug-disease interactions with, 365, 366
 seizures and, 358
 Oxidative stress, 57, 58, 65
 Oxybutynin, 234, 235, 236, 237–238, 246
 Oxycodone, 426–427, 429
 Oxycodone extended release, 134
 Oxycodone immediate release, 133–134
 Oxygen, STEMI, NSTEMI and, 168

P

P. aeruginosa, 525, 529–531
 PACE (Program of All-Inclusive Care for the Elderly), 11, 47
 Pain assessment, 82–83
 Pain management, 418, 424–430
 case, 432–433
 end-of-life, 131–133

- Pain medications, falls and, 441
- Palliative care, 40, 123–124, 126, 149
 consult case, 145–146
 death and dying, 124–125
 end-of-life, 125–126
 nonpharmacologic issues in, 126–128
 pharmacologic issues in, 128–131
 pharmacologic management of symptoms, 131–144
 tailoring medication appropriateness in, 129–130
- Palliative sedation to unconsciousness, 143
- Palonosetron, 306
- Pamidronate, hospice and palliative care, 135
- Panic disorder, 385, 387
- Pap test, 496
- Parasympathomimetic agents, 419, 420
- Parenteral folic acid, 486
- Parenteral iron, 485–486
- Parkinson disease, 159, 338, 348–355, 370
 case, 368–369
- Paroxetine, 383
- Partial response, 378, 381
- Partial seizures, 356
- Patient decision-making, 33
- Patient education, 84
- Patient Health Questionnaires (PHQ), 91
- Patient Self-Determination Act, 37–38
- Patient understanding, assurance of, 34
- PCV13 (pneumococcal conjugate vaccine 13 valent), 491
- Peak-flow meter, 211
- Pegaptanib, 421
- Penicillins, 312, 364
- Penile devices, 281
- Pentamidine, 486
- Pentazocine, high-risk medication, 108
- Pentobarbital, high-risk medication, 107
- Pentoxifylline, 171, 172
- Perampanel, 363
 drug-disease interactions with, 365
 seizures and, 358
- Peripheral arterial disease, 170–172
- Peripheral diabetic neuropathic pain, 425, 426
- Peripheral neuropathy, 271
- Pernicious anemia, 483
- Persistent pain, 424
- Personal health information, 34
- Pertussis, 491–492
- Pharmaceutical Research and Manufacturers of America (PhRMA) 48
- Pharmacodynamics, 70–71
- Pharmacokinetics
 age-related changes in, 68–70
 palliative care and, 128–129
- Pharmacologic management of dying symptoms, 131–33
- Pharmacotherapy adage, 74
- Pharmacy services, 17, 47
 access, 15–16
 brown bag medication, adherence review, 14–15
- Phenobarbital, 362, 455, 486
 drug-disease interactions with, 365, 366
 as high-risk medication, 107
 hypothyroidism and, 277
 palliative sedation and, 144
 seizures and, 358
- Phenothiazines, 140, 305, 364
- Phentermine and topiramate extended release, 262, 273–274
- Phenylephrine, 234
- Phenytoin, 301, 455, 486
 drug-disease interactions with, 365, 366
 hypothyroidism and, 277
 protein binding and, 69
 seizures and, 356, 361–362, 359
- Phobias, 385–386, 388
- Phosphate binders, 226
- Phosphodiesterase (PDE) inhibitors, 246
- Phosphodiesterase type 5 (PDE-5), 281, 283
- Physical activity, 93–94. *See also* Exercise
- Physical assessment, 78–82
- Physical function, 5–6
- Physical therapists, 8, 10
- Physician-assisted suicide, 40
- Phytoestrogens, 499
- Pick disease, 339
- Pilocarpine, 295, 420, 427, 429–430
- Pioglitazone, 225, 261, 266
- Piperacillin/tazobactam plus ciprofloxacin plus vancomycin, 523
- Pirbuterol terbutaline sulfate (oral), 202
- Pitavastatin, 179
- Pittsburgh Sleep Quality Index, 393
- Pituitary gland dysfunction, 278
- Placement issues, 41
- Plan recommendation, 33–34
- Pneumococcal vaccine, 490–491
- Pneumococcal vaccine/immunization, 110, 489, 458
- Pneumonia, 516–517, 528–532, 540
 causative organisms, antibiotic therapy for, 523
- Pneumonia Severity Index, 531
- Polycarbophil, 298
- Polyethylene glycol 133, 309–310, 312, 350, 355
- Polymerase chain reaction (PCR) analysis, 534
- Polymyalgia rheumatica, 456, 459–461
 case, 470–471
- Polypharmacy, 14, 64, 105, 111
 cardiovascular disorders and, 167, 176, 184, 188
 gastroesophageal reflux disease and, 303
 medication-induced bone loss and, 455

- osteoporosis/fractures and, 449
- Polyvenism, 14
- Pooled Cohort Equation, 166
- Post-traumatic stress disorder, 385, 388
- Potassium supplements, 302 GERD and, 303
- PPSV23 (pneumococcal polysaccharide vaccine 23 valent), 491
- Pramipexole, 350, 351, 352, 355
- Pramlintide, 267–268
- Prandin, 261
- Prasugrel, 168
- Pravastatin, 166, 179
- Precose, 261
- Prednisone, 205, 455, 460
- Preferred provider organizations (PPOs), 47
- Pregabalin, 362
 - drug-disease interactions with, 365
 - in hospice and palliative care, 135
 - seizures and, 359
- Pregnancy category X, 302
- Prepopik, 495
- Presbycusis, 63, 418
- Presbyopia, 418, 419
- Prescribing cascade, 114
- Prescription drug abuse, 401–402
- Pressure, 439, 461
- Pressure ulcers, 461–466
- Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS), 183
- Primidone, 362, 486
 - drug-disease interactions with, 365
 - seizures and, 359
- Privacy, 34
- Private health insurance, 44, 45
- Probiotics, 310, 315
- Problem-solving therapy, 378, 382
- Procrit, 487
- Prodigy® glucose monitor, 270
- Programmed theories of aging, 59
- Promethazine, high-risk medication, 107
- Propafenone, 178, 180
- Proportionate palliative sedation, 123, 143–144
- Propranolol, 69
- Propylthiouracil, 262, 273, 275–277
- PROSPER trial, 166
- Prostaglandin analogs, 419–424
- Prostate cancer
 - chemoprevention, 501
 - screening, 496
- Prostate Cancer Prevention Trial (PCPT), 501
- Prostate-specific antigen (PSA) test, 496
- Protein binding, 69
- Proteinuria, 271
- Proteus*, 525
- Proton pump inhibitor, 110, 118, 228, 302, 325
 - absorption and, 68
 - diarrhea and, 313
 - GERD and, 303–304
 - musculoskeletal/connective tissue disorders and, 447, 447, 461
 - nausea/vomiting and, 139
- Providencia sp.*, 526
- Proxy, 30, 38, 39
- Pruritus, 137
- Pseudoephedrine, 233, 234, 243
- Pseudomonas aeruginosa*, 299
- Psychiatric issues, 377–416
- Psychological aging models, 64
- Psychologists, 8
- Psychosocial intervention, 400–401
- Psychotherapy, 386, 389
- Pulmonary assessment, 80
- Pulse pressure, 158, 161
- Puree diet, 299
- Pyelonephritis, 522, 527
- Pyrazinamide, 214
- Pyridoxine, 214
-
- ## Q
- Qsymia, 262
- Quadrivalent vaccine, 488, 490
- Quality of life issues/decisions, 39, 127–128
- Quazepam, 394
- Quetiapine, 338, 344, 348, 355
 - delirium and, 143
 - dementia and, 31
- Quinidine, diarrhea and, 312
- Quinolones, diarrhea and, 312
-
- ## R
- Radioactive iodine (I-131), 276–277
- Raloxifene, 449, 452, 498–499
- Ramelteon, 394–395
- RAND Corporation, 109
- Ranibizumab, 421, 423
- Ranolazine, 133
- Rapid Estimate of Adult Literacy in Medicine (REALM), 83
- Rapid influenza diagnostic tests, 534
- Rasagiline, 350, 351, 352, 353
- Razadyne, 340
- Reactivation, 199, 212, 213
- Recreational therapists, 8
- Recurrence/recurrent infection, 378–379, 516, 524–525, 527
- Refractory epilepsy, 334, 356
- Relapse, 378, 381, 516, 524–525, 527
- Relenza, 490
- Religion, 37

RE-LY trial, 180
 Remission, 378, 380
 Renal changes, 60
 Renal disorders, 222–228
 Repaglinide, 225, 261, 267
 Reserpine >0.1 mg/day, high-risk medication, 107
 Resistance, 521
 Resource Utilization in Dementia, 19
 Respiratory changes, 63
 Respiratory disorders
 asthma, 200–212
 commonly used drugs, 202–206
 COPD, 200–212
 COPD therapy by state, 207
 tuberculosis, 212–214
 Response, 378, 380
 Restrictive diets, 325
 Resveratrol therapy, 65
 Reteplase, 168
 Reverse transcriptase inhibitors, 486
 Rheumatoid arthritis, 456–459
 Rifabutin, 214
 Rifampin, 214
 hypothyroidism and, 277
 tuberculosis and, 213
 Rifampin with pyrazinamide, 214
 Rifamycins, 214
 Rifapentine, 214
 Rifaximin, 307–308, 314
 Rimantadine, 490, 532
 Ringer's lactate, 228
 Risedronate, 449, 451, 453, 455
 Risk Evaluation and Mitigation Strategy (REMS), 402
 Risk-benefit assessment, 5
 Risk-benefit ratio, 54
 Risperidone, 338, 344, 348
 anxiety and, 138
 delirium and, 143
 dementia and, 31
 Rituximab, 457
 Rivaroxaban
 stroke prevention and, 178–180, 182
 venous thromboembolism and, 186, 187
 Rivastigmine, 340, 341, 355
 ROCKET AF trial, 180
 Ropinirole, 350, 351, 352
 Rosiglitazone, 261, 266
 Rosuvastatin
 dyslipidemia and, 166–167
 intensity, 179
 Rotigotine, 350, 351, 352
 Rufinamide
 drug-disease interactions with, 365
 seizures and, 359
 Rules-based thinking, 32

S

S. aureus, 529
S. pneumoniae, 528–529
Saccharomyces boulardii, 315
 Salicylates, topical, 445
 Salmeterol, 204, 208–209
 Salt restriction, 163
 SAME. See Adenosylmethionine
 SANAD Study Group, 357
 Sarcopenia, 293, 316, 317
 Saw palmetto plant extract, 246
 Saxagliptin, 261, 268
 Screen for Caregiver Burden, 19
 Screening Tool to Alert Doctors to Right Treatment (START), 109
 Secobarbital, high-risk medication, 107
 Secondary prevention of coronary events, 168, 169–170
 Secretagogues, 258, 265, 421
 Sedation, 144
 Sedative/hypnotics, 466
 delirium and, 345
 falls and, 441
 functional incontinence and, 230
 Sedatives, 528
 Seizures, 355–366, 370
 Selective beta blocker, 110
 Selective estrogen receptor modulator (SERM), 282, 498
 Selective serotonin receptor inhibitors, 312
 Selective serotonin reuptake inhibitors (SSRIs), 228, 282–283
 anxiety, depression and, 138
 drug-disease interactions with, 108
 functional decline and, 67
 pain/sensory issues and, 344, 353, 355
 pruritus and, 137
 psychiatric uses for, 381–383, 385–386, 389, 391
 Selegiline, 350, 351, 352
 Self-administration, 84
 Self-efficacy, 35
 Senior housing, 11
 SENIORS trial, 174
 Senna, 133, 428
 Sensory changes, 63
 Sepsis, 531
 Septic shock, 531
 Serotonin norepinephrine reuptake inhibitors (SNRIs), 133
 pain/sensory disorders and, 426–427, 430
 psychiatric disorders and, 381, 382, 384, 386, 389
 Sertraline, 384, 389
 Sertraline, depression, 138

- Sertraline, hospice and palliative care, 136
- Sevelamer, 226
- Seven Minute Screen (7MS), 85
- Severe Impairment Battery (SIB), 89
- Sexual activity, 96
- Sexual dysfunction, 263, 280–282
- Shabaz, 12
- Shared decision-making, 37
- Shear, 440, 461, 462
- Shingles. *See* Herpes zoster
- Short Michigan Alcoholism Screening Test–Geriatric (SMAST–G), 398
- Short-acting beta agonists (SABA), 201, 202, 207, 208
- Sildenafil, 159, 246, 263, 280–281
- Silicone injection, 311
- Silodosin, 234, 244, 245
- Simvastatin, 167, 179
- Sitagliptin, 261, 268
- Situation, Background, Assessment, and Recommendation (SBAR), 113
- 6-mercaptopurine, 486
- Sjögren syndrome, 294, 456
- Skilled nursing facility, 12
 - ethics case, 49–50, 50–51
- Skin
 - assessment, 80
 - changes, 62
- Sleep
 - attacks, 353
 - diaries/questionnaires, 393
 - efficiency, 378, 392
 - restriction, 378, 394
- Sleeper, Rebecca B., 3–28, 293–332, 515–544
- SMART trial, 208
- Smell changes, 63
- Smoking cessation, 201, 218
- SNRIs. *See* Serotonin norepinephrine reuptake inhibitors
- Social anxiety disorder, 385, 387
- Social assessment, 94–96
- Social functioning aging model, 64
- Social history, 94–95
- Social Security
 - benefits, 4
 - insurance coverage and, 95
- Social workers, 8
- Socioeconomic considerations, 29–30, 42, 44
- Sodium, water imbalance, 225
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors, 262–263, 265, 268
- Solifenacin, 232, 233, 234
- Sorbitol, 299, 310 diarrhea and, 312
- Sotalol, 178, 180
- Southeast Asian culture, 35
- Speech therapists, 8, 10
- Spirituality, 37, 123, 127–128
- Spirometry, 199, 201
- Spironolactone, 176, 312
- SSRIs. *See* Selective serotonin reuptake inhibitors
- St. John's wort, 364
- St. Louis University Mental Status (SLUMS)
 - Examination, 84, 85, 88
- Standard benefit, 44
- Stanford Geriatric Education Center, 35
- STAR-D study, 380–82
- Starlix, 261
- Start low, and go slow, 74
- State Pharmacy Assistance Programs (SPAPs), 48
- State Units on Aging, 19
- Statins, 110, 225–226, 448
 - diabetes and, 269
 - elderly and, 32
 - functional decline and, 66
 - as inappropriate medication, 130
 - lipid management and, 165–167
 - memory loss and, 167
 - therapy intensity of, 179
 - underuse of, 109
- Status epilepticus, 355–356, 361
- Stavudine, 486
- ST-Elevation Myocardial Infarction (STEMI), 168–169
- Stendra, 263
- Steroids
 - anxiety and, 381
 - depression and, 381
 - functional decline and, 66
 - psychosis and, 133
 - terminally ill and, 133
- Stevens-Johnson syndrome, 363, 446
- Stimulants, 141
- Stool softeners, 309, 310, 428
- STOPP (Screening Tool of Older Person's Prescriptions), 108
- Streptococcus pneumoniae*, 490
- Streptococcus spp.*, 299
- Streptokinase, 168
- Stress incontinence, 230–233, 362
- Stroke, 182–185
 - prevention, 178–179
- Subclinical hypothyroidism, 276
- Suboptimal drug use, 106–110
 - case, 116–117
- Substance Abuse and Mental Health Services Administration Treatment Improvement Protocol, 397
- Substance use disorders, 396–402
- Successful aging, 57, 64–65
- Sucralfate, 301
- Suicide risk, 380
- Sulfasalazine, 486
- Sulfonylurea, 224, 263–267, 270–274

Sulfonylurea with metformin, 224
 Sundowning, 142
 Supportive therapy, 378, 382
 Surgeon General, physical activity guidelines, 93
 Surrogate decision-making, 37–39
 Swallow evaluations, 298–299
 Swallowing, 6
 Swedish Trial in Old Patients with Hypertension (STOP), 162
 Sympathomimetics, anxiety and, 381
 Symptom assessment, 128
 Synthroid, 262
 Systolic Hypertension in Europe (Syst-Eur), 162
 Systolic Hypertension in the Elderly Program (SHEP), 162, 269

T

T cells, 516–517
 T3 (triiodothyronine), 258, 262, 276–277
 T3/T4, 262
 T4 (thyroxine), 258, 276–277
 Tadalafil, 246, 263, 280–281
 Taflopurost, 422
 Tai Chi, 394, 442
 Tamiflu, 490, 498–499
 Tamoxifen, 381
 Tamsulosin, 234, 244–246
 Tapazole, 262
 Tapentadol, 134
 Tapered dosing, 112, 114, 131
 Taste changes, 63
 Telomere theory of aging, 58–59
 Temazepam, 394
 Temporal arteritis. *See* Giant cell arteritis
 Tenecteplase, 168, 169
 Terazosin, 234, 237, 244–245
 Teriparatide, 449, 452, 453, 454, 455
 Terminal secretions, 123, 143
 Test of Functional Health Literacy in Adults (TDFHLA), 83
 Testim, 282
 Testosterone cypionate, 282
 Testosterone enanthate, 282
 Testosterone gel, 279, 282
 Testosterone therapy, 243, 280–282, 449
 Tetanus, 491, 506
 Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine, 110, 489, 491
 Tetracyclines, 312
 Theophylline, 228
 anxiety and, 381
 central nervous system and, 364
 diarrhea and, 312
 GERD and, 303
 respiratory disorders and, 201, 204, 207, 212, 218
 Therapeutic duplication, 115
 Therapeutic failure, 105–106, 112
 Therapeutic Failure Questionnaire, 112
 Thiamin supplementation, 400
 Thiazide diuretics, 164
 hypertension and, 161–163
 renal/urologic issues and, 176, 227–228
 Thiazolidinedione, 225
 Thiazolidinediones (TZDs), 31, 225, 263–264, 266
 Thioridazine, high-risk medication, 108
 Third-party insurance, 16
 Thrombolytic therapy, 158, 183–186
 Thyroid disease, 274–278
 Thyroid disorders medications, 262
 Thyroid hormones, 382
 anxiety and, 381
 diarrhea and, 312
 Thyroiditis, 258, 274
 Thyroid-stimulating hormone (TSH), 258, 275–277, 455
 Thyroxine (T4), 258, 276–277
 Tiagabine, 363
 drug-disease interactions with, 365, 366
 seizures and, 359
 Ticlopidine
 diarrhea and, 312
 as high-risk medication, 107
 stroke prevention and, 183
 Tigecycline, 314
 TIME-CHF trial, 174
 Timed Up and Go Test (TUG), 77, 93, 441
 Timing hypothesis, 278–279
 Timolol, 420, 422
 Timolol plus dorzolamide, 422
 Timolol plus latanoprost, 422
 Tinzaparin, venous thromboembolism and, 187
 Tiotropium, 202, 211
 Tirofiban, 169
 Tirosint, 262
 Tissue plasminogen activator (t-PA), 183–184
 Tobacco use, 94, 447
 Tobramycin, 523
 Tolazamide, 261
 Tolbutamide, 261
 Tolcapone, 350, 353
 Tolinase, 261
 Tolterodine, 234–238, 246
 TONE trial, 163
 Tonic-clonic seizure, 356, 357
 Tool to Improve Medications in the Elderly via Review (TIMER®), 114
 Topical estrogen, 233
 Topical beta blockers, 419, 420
 Topical local anesthetics, 133
 Topiramate
 central nervous system issues and, 357, 360, 363, 370

drug-disease interactions with, 365, 366
 seizures and, 359
 TORCH trial, 208, 209
 Torsades de pointes, 71, 178
 Tramadol, 134, 364, 402, 427, 444–445
 Transdermal patches, absorption and, 68
 Transdermal testosterone, 281
 Transesophageal echocardiogram (TEE), 178
 Transferrin, 480, 483
 Transitions in care, 118
 Transparent bio-occlusive films, 462, 464
 Transportation assessment, 96
 Transurethral resection of the prostate (TURP), 247
 Travoprost, 420
 Trazodone, 395
 Triamcinolone, 203
 Triamcinolone hexacetonide injection, 445
 Triamterene, 486
 Triazolam, 394
 Tricyclic antidepressants, 138

- central nervous system and, 351, 355, 364
- drug-disease interactions with, 108
- dying patient and, 133
- endocrine disorders and, 271
- gastrointestinal disorders and, 294, 301
- musculoskeletal/connective tissue disorders and, 466
- orthostatic hypotension and, 159
- pain/sensory disorders and, 426–428, 430, 434
- pharmacodynamic changes, recommendations, 71
- psychiatric issues and, 382–383, 385–386
- renal/urologic disorders and, 243

 Trihexyphenidyl, 350, 354

- as high-risk medication, 107

 Triiodothyronine (T3), 258, 262, 276–277
 Trimethobenzamide, 305

- as high-risk medication, 108

 Trimethoprim, 70, 486, 523
 Trimethoprim/sulfamethoxazole, 523, 525
 Trimipramine, high-risk medication, 107
 Triprolidine, high-risk medication, 107
 Trivalent influenza vaccine, 488, 490, 533
 Trolamine salicylate, topical, 445
 Tropisetron, 306
 Tropicium, 234, 236
 Tube medications, 301
 Tuberculin skin test, 212, 213

- two-step, use of, 71

 Tuberculosis, 212–214, 458

- treatment agents, 214

 TUG. *See* Timed Up and Go Test
 Tumor necrosis factor alpha, 482
 Tylenol, 430

U

U.S. Physician's Health Study, 500
 U.S. Preventive Services Task Force (USPSTF), 79, 81, 84, 494–497
 Underuse of medications, 106, 109
 Unexplained anemia, 482, 484–487
 Unfractionated heparin, 168, 169, 186
 United Kingdom Prospective Diabetes Study, 270
 United Kingdom Transient Ischaemic Attack Aspirin Trial, 499
 Unnecessary medication, 106
 Upper age limit, 5
 Urethritis, 522
 Urge urinary incontinence, 231, 234
 Urinalysis, 522
 Urinary incontinence, 228–230, 259–260

- case, 248–249
- nonpharmacologic treatments for, 232–233
- pharmacologic treatments for, 233–238
- surgery for, 238
- types of, 230–232

 Urinary tract infections (UTIs), 516–518, 522–528

- case, 536–537
- causative organisms, antibiotic therapy for, 523

 Urologic assessment, 81
 Urologic diseases/disorders, 238–239

- dementia/incontinence case, 248–249

 Utah Medicaid and Medicare database study, 531

V

Vaginal cream, 234
 Vaginal lubricants, 282
 Valproate, 356–357, 365–366
 Valproic acid, 344, 359, 362, 427, 486
 Van Gorkom, Kelsey L., 515–544
 Vancomycin, 63, 314, 315
 Vancomycin-resistant enterococci, 518
 Vardenafil, 246, 281
 Vascular cognitive impairment, 338
 Vascular dementia, 338
 Vascular endothelial growth factor inhibitors, 423
 Vasodilators, 159, 163
 Venlafaxine, 135, 364, 384, 389–390, 427
 Venous thromboembolism, 185–188
 Ventricular rate control, 178
 Verapamil, 69, 178, 277
 Verbal Rating Scale, 83
 Veterans Affairs, Department of, 47, 85, 106
 Veterans' benefits, 45
 Viagra, 263
 Videofluoroscopic Swallow Study, 298
 Vigabatrin, 363

- drug-disease interactions with, 365

seizures and, 359
 Viridans group streptococci, 518
 Vision impairment, 418–424
 case, 431
 Visual changes, 63
 Vital signs, 79
 Vitamin B12, 265, 400, 506
 Vitamin B12–deficiency anemia, 335, 482–484, 486, 488
 Vitamin C, 524–525
 Vitamin D, 441–442, 446, 450, 454–455, 482
 Reduce kidney function and, 70
 supplementation, 500
 Vitamin dietary intakes, 320
 Vitamin E, 113
 Volume of distribution, 69, 129
 Voluntariness, patient, 33
 Vomiting, 138–140, 304–306

W

Warfarin, 181, 182
 adverse drug events and, 113
 cognitive function and, 6
 dosing of, 71
 falls and, 472
 gastrointestinal disorders and, 296, 301
 protein binding and, 69
 sensitivity of, 306
 stopping, 131
 stroke prevention and, 178–180, 183
 underuse of, 109
 venous thrombosis and, 186–188
 Wear-and-tear theory of aging, 58
 Wearing off, 334, 349, 351
 Weight loss, 272–274, 316–317
 Wernicke encephalopathy, 397
 Wickham survey, 276
 White blood cell count evaluation, 520
 White-coat hypertension, 162
 Widower effect, 18
 Withdrawing treatments, 40
 Withholding treatments, 40
 Women's Health and Aging Study, 487
 Women's Health Initiative, 278–279
 Woodstock Generation, 36
 World Health Organization, 425, 480, 485, 533

X

Xanthines, insomnia and, 381
 Xenical, 262
 Xerostomia, 293, 294–295

Y

“Young-old,” 5

Z

Zafirlukast, 205
 Zaleplon, 394
 as high-risk medication, 108
 Zanamivir, 490, 532, 534
 Zarit Index, 19
 Zeaxanthin, 422, 423
 Zidovudine, 486
 Zileuton, 205
 Zinc, 423
 Zinc oxide, 313
 Ziprasidone, 31, 348
 Zoledronic acid, 135, 449, 451, 453–455
 Zolpidem, 394
 as high-risk medication, 108
 Zonisamide, 363
 drug-disease interactions with, 365, 366
 seizures and, 356, 359

